| Expression pattern: |
UP |
| Associated gene: |
NCK2, CBL, STAM2 |
| Associated microRNA: |
- |
| Biological function: |
associated with CLL cancer progression (possible impacts on angiogenesis, B-cell activation, and EGFR signaling) |
| Molecular mechanism: |
bioinformatically inferred interaction with NCK2/CBL/STAM2 impacting angiogenesis, B-cell activation, and EGFR signaling pathway |
| Biological pathway or process: |
angiogenesis (other); EGFR (other); other pathway/process (other) |
| Detected method: |
S
|
| Validation methods: |
RNA-seq; Bioinformatics Analysis; ROC Analysis; Survival Analysis; Cohort Study |
| Clinical significance: |
Diagnostic biomarker (AUC reported) and prognostic association with 5-year OS (high level associated with worse OS). |
| Description: |
circMYH9 is increased in CLL and is part of a four-circRNA diagnostic/prognostic signature. Network analysis links circMYH9 with NCK2/CBL/STAM2 and suggests impacts on angiogenesis, B-cell activation and EGFR signaling; higher expression is associated with worse OS in validation cohorts. |
| Confidence score: |
0.5121 |